Lexeo Therapeutics, Inc. (LXEO) Presents at forty fourth Annual J.P. Morgan Healthcare Convention Transcript

Tessa Romero
JPMorgan Chase & Co, Analysis Division

Welcome, everybody, to the forty fourth Annual JPMorgan Healthcare Convention. My title is Tessa Romero, and I am one of many senior biotech analysts right here at JPMorgan. We’re happy to welcome our subsequent presenting firm, Lexeo Therapeutics, to kick off our Wednesday. And presenting on behalf of the corporate, we’ve CEO, Nolan Townsend. Nolan, over to you.

R. Townsend
CEO & Director

Thanks, Tess. It is nice to be right here, and thanks, everybody, for coming. We will begin with a brief video to offer a taste of the kind of illnesses that Lexeo Therapeutics is searching for to deal with.

[Presentation]

R. Townsend
CEO & Director

These are actual sufferers fighting a really troublesome illness. And the mission of Lexeo Therapeutics is to ship therapies to deal with sufferers with difficult illnesses precisely like this one. We’re an organization devoted to reshaping coronary heart well being. Our first program is in Friedreich’s ataxia, however we anticipate to have an effect on different illnesses of an identical profile over time. We’re doing this by constructing one of many main cardiac genetic medicines platform. The corporate has a deep experience in cardiac genetic medication, every part from scientific trials to manufacturing by means of to preclinical improvement.

We have now a differentiated supply system within the AAVrh10 capsid. It is a extremely cardiotropic vector. It is splendid for treating illnesses of the center. We have now an modern manufacturing platform that is capable of provide each small and huge indications with cardiac illness. And we’ve a robust monetary place and working expertise